Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: An analysis conducted on the UK General Practitioner Research Database

Journal of Medical Economics

Volumn 11, Issue 3, 2008, Pages 485-497

  Lafuma, Antoine ^a   Laurendeau, Carolini ^a   Berdeaux, Gilles ^b  

^a CEMKA EVAL   (France)

^b Alcon France   (France)

Author keywords

Brimonidine; Brinzolamide; Costs; Economics; Effectiveness; Glaucoma

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; PROSTACYCLIN DERIVATIVE;

AGED; ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIMARY MEDICAL CARE; SCORING SYSTEM; TREATMENT DURATION; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

ADRENERGIC ALPHA-AGONISTS; AGED; CARBONIC ANHYDRASE INHIBITORS; COMORBIDITY; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INSURANCE CLAIM REVIEW; MALE; QUINOXALINES; SULFONAMIDES; THIAZINES; TIME FACTORS;

EID: 55049128298     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990802211107     Document Type: Article

References (31)

1. Diestelhort JS, Hughes GM. Open-angle glaucoma American Family Physician 2003; 67: 1937-1944.
2. Hattenhauer MG, Johnson DH, Ing HH et al. The probability of blindness from open-angle glaucoma. Ophthalmology 1998; 105: 2099-2104.
3. Broman AT, Quigley HA. The number of people with glaucoma worldwide in 2010 and 2020. British Journal of Ophthalmology 2006; 90:253-254.
4. Coyle D, Drummond M. The economic burden of glaucoma in the UK The need for a far-sighted policy. Pharmacoeconomics 1995; 7: 484-489.
5. Kobelt G, Jonsson L, Gerdtham U et al. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefe's Archive for Clinical and Experimental Ophthalmology 1998; 236: 811-821.
6. Denis P, Lafuma A, Berdeaux G. Medical predictive factors of glaucoma treatment costs. Journal of Glaucoma 2004; 13: 283-290.
7. Kooner KS, Zimmerman TJ. The cost of antiglaucoma medications. Annals of Ophthalmology 1987; 19: 327-328.
8. Vold SD, Riggs WL, Jackimiec J. Cost analysis of glaucoma medications: a 3-year review. Journal of Glaucoma 2002; 11: 354-358.
9. Fiscella RG, Geller JL, Gryz LL et al. Cost considerations of medical therapy for glaucoma. American Journal of Ophthalmology 1999; 128: 426-433.
10. Jönsson B, Krieglstein G. Primary open-angle glaucoma - differences in international treatment patterns and costs, Oxford: Isis Medical Media Ltd, 1998.
11. Kass MA, Heuer DK, Higginbotham EJ et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of Ophthalmology 2002; 120: 701-713.
12. The European Glaucoma Prevention Study (EGPS) group. Results of the European Glaucoma Prevention Study. Ophthalmology 2005; 112: 366-375.
13. The AGIS investigators. The Advanced Glaucoma Intervention Study (AGIS). Report #13: Comparison of treatment outcomes within race: 10-year results. Ophthalmology 2004; 111: 651-664.
14. Heijl A, Leske MC, Bengtsson B et al. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology 2002; 120: 1268-1279.
15. Leske MC, Heijl A, Hussein M et al. Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Archives of Ophthalmology 2003; 121: 48-56.
16. Hjelmgren J, Berggren F, Andersson D. Health economics guidelines - similarities, differences and some implications. Value in Health 2001; 4: 225-250.
17. Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Current Medical Research and Opinion 2006; 22: 971-976.
18. Deschaseaux-Voinet C, Laftima A, Berdeaux G. Cost and effectiveness of brinzolamide versus dorzolamide in current practice: an analysis based on the UK-GPRD data base. Journal of Medical Economics 2003; 6: 69-78.
19. Wilensky J, Fiscella RG, Carlson AM et al. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. American Journal of Ophthalmology 2006; 141(1 Suppl.): S28-33.
20. Nordstrom BL, Friedman DS, Mozaffari E et al. Persistence and adherence with topical glaucoma therapy American Journal of Ophthalmology 2005; 140: 598-606.
21. GPRD website. Available at: http://www.gprd.com/home/
22. Reis R, Queiroz CF, Santos LC et al. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Clinical Therapeutics 2006; 28: 552-559.
23. Yue LQ. Statistical and regulatory issues with the application of propensity score analysis to nonrandomized medical device clinical studies. Journal of Biopharmaceutical Statistics 2007; 17: 1-13; discussion 15-17, 19-21, 23-27 passim.
24. BNF website. Available at: http://www.bnf.com
25. Statistics of OECD. Available at: http://www.oecd.org/
26. Curtis L, Netten A. Units costs of health and social care 2005 PSSRU University of Kent. (http://www.pssru.ac.uk/)
27. European Medicines Agency. European Public Assessment Report (EPAR). Available at: http://www.emea.europa.eu/htms/human/epar/a.htm
28. Vidal. Edition du Vidal. Paris, France, 2006.
29. Roulland JF, Le Pen C, Gouveia Pinto et al. Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open glaucoma in 4 European countries. PharmacoEconomics 2003; 21: 201-213.
30. Friedman DS, Quigley, Gelb A et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Investigative Ophthalmology and Visual Science 2007; 48(11): 5052-5057.
31. Quigley HA, Friedman DS, Hahn SR. Evaluation of practice patterns for care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study. Ophthalmology 2007; 114(9): 1599-1606.